Citations

Showing 10 of 108152 citations.

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial
Kahaly, George J. , Stan, Marius N. , Frommer, Lara, Amer, Ahmed , Schuhmann, Imelda , Espié, Pascal, Rush, James S. , Basson, Craig T. , He, Yanling , Stan, Marius Nicolae, Stan, Marius N , Gergely, Péter Attila , Colin, Laurence , Amer, Ahmed

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 12, 2019 | Volume: 105 | Issue: 3 | Pages: 696-704

10.1210/clinem/dgz013 | PMID 31512728 Get It

Abstract Context The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. Objective Evaluate efficacy and safety of a human, blocking, nondepleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD. Design Open-label, phase II proof-of-concept study. Setting Multicenter. Patients Fifteen with GD. Intervention Patients received 5 doses of iscalimab at 10 mg/kg intravenously over 12 weeks. Main outcome measures Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. Results The iscalimab intervention resulted in complete CD40 engagement for up to 20 weeks. A clinical response and biochemical euthyroidism was observed in 7 of 15 (47%) patients. Free and total triiodothyronine and thyroxine normalized in 7 patients who did not receive any rescue medication with antithyroid drugs (ATD), and 2/15 (13.3%) showed normal thyrotropin. Six (40%) patients required ATD. Four of 7 responders relapsed after treatment completion. Serum concentrations of thyrotropin receptor autoantibodies (TSH-R-Ab) significantly declined in all patients (mean 15.3 IU/L vs 4.0 IU/L, 66% reduction; P < 0.001) and TSH-R-Ab levels normalized in 4 (27%). Thyroperoxidase and thyroglobulin autoantibodies significantly decreased in responders. Iscalimab rapidly reduced serum CXCL13 concentrations (P < 0.001). Twelve (80.0%) patients reported at least 1 adverse event (AE). All treatment-related AE were mild or moderate and resolved by end of the study. Conclusion Iscalimab was generally safe and clinically effective in a subgroup of hyperthyroid GD patients. The potential therapeutic benefit of iscalimab should be further tested.
Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity
Graff‐Radford, Jonathan , Przybelski, Scott A. , Lesnick, Timothy G. , Preboske, Gregory M., Senjem, Matthew L. , Gunter, Jeffrey L. , Kantarci, Kejal , Petersen, Ronald C. , Jack, Clifford R. , Vemuri, Prashanthi , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Scharf, Eugene , Mielke, Michelle M. , Knopman, David S. , Schwarz, Christopher G. , Machulda, Mary M.

Mayo Clinic

Stroke | September 12, 2019 | Volume: 50 | Issue: 11 | Pages: 3037-3044

10.1161/strokeaha.119.025822 | PMID 31510903 Get It

Background and Purpose— White matter hyperintensity (WMH) burden is associated with stroke and cognitive decline. Risk factors associated with the longitudinal progression of WMH in the general population have not been systematically investigated. To investigate the primary midlife and current cardiometabolic risk factors associated with changes in WMH over time in a population cohort. Methods— This cohort study included participants enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study in Olmsted County, Minnesota with at least 2 consecutive WMH assessments on fluid-attenuated inversion recovery-magnetic resonance images (n=554, ≥60 years with midlife assessments) with relevant baseline laboratory measures of interest. Linear mixed model regression was used to determine the important components of cardiometabolic risk profile at baseline that were associated with future progression of WMH. These analyses were controlled for age and sex. Sensitivity analyses were conducted using stratification by sex. The main outcome measure was percent change in WMH normalized to total intracranial volume. Three sets of models were constructed to evaluate individual (1) midlife risk factors, (2) current risk factors including the presence of metabolic syndrome and its constituents, and (3) baseline measurements of continuous laboratory measures of cardiometabolic risk. Results— Age was the strongest predictor of progression in WMH ( P <0.001). Baseline hypertension ( P <0.001), midlife hypertension ( P =0.003), and baseline fasting glucose in males ( P =0.01) were predictive of WMH change. The presence of metabolic syndrome was not associated with progressive WMH. In sensitivity analyses, associations between hypertension and WMH progression were stronger in females. Baseline serum glucose was associated with increase in WMH but was not significant in females in the stratified analysis. Other continuous laboratory measures of vascular risk were not associated with progressive WMH. Conclusions— Midlife and current hypertension in all participants and fasting glucose in males were associated with quantitative changes in white matter. Prospective clinical studies should determine optimal blood pressure to reduce stroke and cognitive impairment during aging.
Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volume—Brief Report
Syrjanen, Jeremy A. , Bui, Hai H., Petersen, Ronald C. , Jack, Clifford R. , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R , Vemuri, Prashanthi , Mielke, Michelle M. , Knopman, David S.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | September 12, 2019 | Volume: 39 | Issue: 11 | Pages: 2431-2436

10.1161/atvbaha.119.313099 | PMID 31510790 Get It

Objective: Sphingolipids, including S1P (sphingosine-1-phosphate) and ceramides, have been associated with vascular tone, blood pressure regulation, cardiovascular outcomes, and mortality. However, the relationship between plasma sphingolipids and cerebrovascular disease has not been examined. We aimed to assess the cross-sectional association between plasma sphingolipids and white matter hyperintensity (WMH) volume, which is a marker of cerebrovascular disease. Approach and Results: We included 588 participants (302 men and 286 women), aged 60 to 93, enrolled in the population-based Mayo Clinic Study of Aging who had MRI and plasma sphingolipids at the same study visit. Fasting plasma was obtained, and ceramides and S1P were assayed using liquid chromatography-electrospray ionization tandem mass spectrometry. Fluid-attenuated inversion recovery was used to measure WMH volume, defined as percent total intracranial volume. We used linear regression to cross-sectionally examine the relationships between plasma sphingolipids and WMH; both were log-transformed. In multivariable analyses adjusting for age, sex, and hypertension, higher levels of ceramide C16:0 (b [95% CI]=0.24 [0.02–0.45]) and the ceramide ratios C16:0_24:0 (b [95% CI]=0.30 [0.12–0.48]) and C24:1_24:0 (b [95% CI]=0.24 [0.07–0.41]) were associated with a higher WMH volume. A higher ceramide score was also associated with higher WMH volume (b [95% CI]=0.03 (0.01–0.04]). We did not observe any association between S1P and WMH volume. Conclusions: Higher plasma ceramide C16:0 and 2 specific ceramide ratios (C16:0_24:0 and C24:1_24:0) are associated with greater WMH volumes, independent of hypertension, suggesting their utility for measurement of cerebrovascular disease.
Incidence and Natural History of Left Bundle Branch Block Induced Cardiomyopathy
Barake, Walid , Witt, Chance M. , Vaidya, Vaibhav R. , Cha, Yong‐Mei

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 12, 2019 | Volume: 12 | Issue: 9 | Pages: No page available

10.1161/circep.119.007393 | PMID 31510788 Get It

Faculty Opinions recommendation of Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bajpai, Shilpika , Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.736200610.793564799 Get It

Integrating pharmacogenomics into the electronic health record by implementing genomic indicators
Sutton, Joseph , Giri, Jyothsna , Wright, Jessica , Nicholson, Wayne T. , Parkulo, Mark A. , Bielinski, Suzette J. , Moyer, Ann M. , Caraballo, Pedro J. , Sutton, Joseph A, Wright, Jessica A, Bielinski, Suzette , Wright, Jessica A , Kullo, Iftikhar J.

Mayo Clinic

Journal of the American Medical Informatics Association | September 12, 2019 | Volume: 27 | Issue: 1 | Pages: 154-158

10.1093/jamia/ocz177 | PMID 31591640 Get It

Abstract Pharmacogenomics (PGx) clinical decision support integrated into the electronic health record (EHR) has the potential to provide relevant knowledge to clinicians to enable individualized care. However, past experience implementing PGx clinical decision support into multiple EHR platforms has identified important clinical, procedural, and technical challenges. Commercial EHRs have been widely criticized for the lack of readiness to implement precision medicine. Herein, we share our experiences and lessons learned implementing new EHR functionality charting PGx phenotypes in a unique repository, genomic indicators, instead of using the problem or allergy list. The Gen-Ind has additional features including a brief description of the clinical impact, a hyperlink to the original laboratory report, and links to additional educational resources. The automatic generation of genomic indicators from interfaced PGx test results facilitates implementation and long-term maintenance of PGx data in the EHR and can be used as criteria for synchronous and asynchronous CDS.
Mechanisms underlying TNFα‐induced enhancement of force generation in airway smooth muscle
Young‐Soo, Han, Valencia, Sara Osorio , Delmotte, Philippe , Doğan, Murat , Young-Soo, Han, Osorio Valencia, Sara, Delmotte, Philippe , Sieck, Gary C.

Mayo Clinic

Physiological Reports | September 12, 2019 | Volume: 7 | Issue: 17 | Pages: No page available

10.14814/phy2.14220 | PMID 31512410 Get It

A Novel Anti-Cd40 Monoclonal Antibody, Iscalimab, for Control of Graves’ Hyperthyroidism – A Proof-Of-Concept Trial
Kahaly, George J. , Frommer, Lara, Amer, Ahmed , Schuhmann, Imelda , Espié, Pascal, Rush, James S. , Basson, Craig T. , He, Y L , Stan, Marius N. , Gergely, Péter Attila , Colin, Laurence , Amer, A

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/jcem/dgz013 Get It

Abstract Context The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves’ disease (GD) by promoting auto-reactive B cell activation. Objective Evaluate efficacy and safety of a human, blocking, non-depleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD Design Open label, phase II proof-of-concept study Setting Multicenter Patients Fifteen with GD Intervention Patients received five doses of iscalimab at 10 mg/kg intravenously over 12 weeks. Main outcome measures Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. Results The iscalimab intervention resulted in complete CD40 engagement for up to 20 weeks. A clinical response and biochemical euthyroidism was observed in seven of 15 (47%) patients. Free and total T3 and T4 normalized in seven patients who did not receive any rescue medication with anti-thyroid drugs (ATD), and 2/15 (13.3%) showed normal TSH. Six (40%) patients required ATD. Four of seven responders relapsed after treatment completion. Serum concentrations of thyrotropin receptor autoantibodies (TSH-R-Ab) significantly declined in all patients (mean 15.3 IU/L versus 4.0 IU/L, 66% reduction, P<0.001) and TSH-R-Ab levels normalized in four (27%). Thyroperoxidase and thyroglobulin autoantibodies significantly decreased in responders. Iscalimab rapidly reduced serum CXCL13 concentrations (P<0.001). Twelve (80.0%) patients reported at least one adverse event (AE). All treatment-related AE were mild or moderate and resolved by end of the study. Conclusion Iscalimab was generally safe and clinically effective in a subgroup of hyperthyroid GD patients. The potential therapeutic benefit of Iscalimab should be further tested.
Neurochondrin neurological autoimmunity
Shelly, Shahar , Kryzer, Thomas J., Komorowski, Lars , Miske, Ramona , Anderson, Mark D. , Hinson, Shannon R., Lennon, Vanda A. , Pittock, Sean J. , Pittock, S J , Shahar, Shelly , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | September 11, 2019 | Volume: 6 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000612 | PMID 31511329 Get It

A Contemporary Systematic Approach to Assessing the Patient with Heart Failure with Reduced Ejection Fraction: Multimodal Noninvasive and Invasive Evaluation
Wan, Siu‐Hin , Bois, John P. , McKie, Paul M. , Bois, John P

Mayo Clinic

Cardiology Research and Practice | September 11, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-12

10.1155/2019/3039740 | PMID 31612081 Get It

Heart failure with reduced ejection fraction (HFrEF) is a progressive clinical syndrome commonly associated with left ventricle dilatation and characterized by reduced cardiac output, secondary pulmonary and systemic venous congestion, and inadequate peripheral oxygen delivery. It is common yet complex and requires synthesis of evidence-based guidelines along with strong clinical acumen. The following is a review of an illustrative case that highlights the important clinical considerations in diagnosis, assessment, and management of HFrEF commonly encountered in practice. Explanations provided highlight of the relevant pathophysiology of HFrEF as well as detailed explanations of interpretation of examinations and both noninvasive and invasive assessment in heart failure. The example provided would hopefully serve as a potential point of reference for trainees as well as healthcare practitioners for patients with HFrEF.